

Well placed and cash rich

Few capital goods companies are better positioned than Mpac to survive the COVID-19 induced downturn, exploit opportunities that arise and flourish when the economy eventually gets back on its feet (hopefully in 2021). Why?


Firstly this high speed packaging & automation solution firm sports a £18.1m net cash balance (or 89p/share as at Feb'20), on top of an undrawn £10m credit facility. Providing ample fire-power to not only weather even the most extreme of scenarios, but also take advantage if some less well capitalised rivals ever became available at distressed levels.

What's more, with a global footprint and fully integrated smart technology (eg remote diagnostics, firmware, etc) underpinning its industry leading products, there should be further scope to gain market share organically, as clients standardise on best-in-class OEMs offering worldwide service & support.

In fact this may already be happening, since we understand Mpac is still winning new business despite a small number of orders being deferred because of the pandemic.

Covering vital machinery, spares & engineering expertise to strategically important sectors like healthcare, pharmaceuticals and food/beverage (see below), which are needed to keep people healthy & fed throughout this challenging period.

2019 revenue (£88.8m) break-down by customer segment



Source: Equity Development

Shares are attractively priced

In the meantime, the Board is sensibly cutting its cloth – namely reducing/deferring capex (£2.3m 2019) and discretionary spend, alongside utilising available government aid programs. Mindful however not to harm long term design and operational capability.


With regards to valuation, the stock at 235p remains attractively priced - trading on a 2019 EV/EBIT multiple of 7.4x (see below) vs 11x–15x typically for peers (pre CV19).

6th May 2020

Company Data

EPIC	AIM:MPAC
Price (last close)	235p
52 week Hi/Lo	367p/154p
Market cap	£47.4m
Net cash Dec '19	£18.0m
Share count (incl Treasury)	20.172m
ED valuation/share	Withdrawn
Avg. daily volume	250,000

Share Price, p



Source: Share Cast

Description

Mpac is a specialist provider of **full line, high speed packaging & automation solutions**, employing c. 510 staff.

The group not only develops & manufactures niche factory equipment and robotics, but also undertakes turnkey projects involving the design & integration of such systems. More than 80% of revenues are generated outside of the UK, hence providing a natural hedge against sterling weakness.

Core verticals are Healthcare, Pharmaceutical and Food/Beverage, supporting the likes of 3M, J&J, Nestlé, GSK, P&G, Philips Advent, ConvaTec, AstraZeneca, Unilever, Kellogg's, Diageo, Ferrero, Bausch + Lomb & CooperVision.

Next news: Trading update mid July

Paul Hill (Analyst)

paul.hill@equitydevelopment.co.uk

Sure the coronavirus will impact 2020 numbers, yet ultimately we believe Mpac will prosper. Benefitting from secular tailwinds (eg Industry 4.0, Direct-to-consumer deliveries), improving margins, a large installed base, positive cashflows and a host of loyal, blue-chip customers.

Range of sector valuation benchmarks pre COVID-19 crisis

	Mpac 2019 Trailing	Typical Packaging equipment & Engineering multiples pre COVID-19	
		Low	High
EV/Sales (pension adjusted)	0.6	1.0	1.5
EV/EBITDA (pension adjusted)	5.8	8.0	12.0
EV/EBIT (pension adjusted)	7.4	11.0	15.0
PER	5.9	14.0	18.0
EBIT margin	8.7%	10.0%	15.0%

Source: Equity Development


The world is gradually getting back to work

Elsewhere, the actuarial deficit on the UK pension scheme (re £35.2m as at the June 2018 triennial valuation) may have increased slightly over the past 2 months – reflecting lower gilt yields, higher spreads on corporate bonds and the recent equity market turmoil.

That said, the worst of March's credit crunch seems to be behind us, thanks to massive central bank intervention and 'do whatever it takes' monetary stimulus.

From a medical perspective too, encouraging progress is being made on tackling the disease (re flattening the curve). Thus allowing several countries to slowly reboot their economies. Indeed over the past week, roughly 20 US states have tentatively lifted 'stay-at-home' orders, Mpac's largest region (see below). Which hopefully will further prompt the UK & the rest of Europe set to follow suite in the not too distant future, after similar moves from Germany & Denmark.

2019 regional sales (£88.8m) split



Source: Equity Development

Key risks

- COVID-19 impacts last longer than expected. Plus in past recessions, capital equipment volumes are typically exposed to the cyclical nature of the global economy.
- The large size of the UK (£403.2m of liabilities as at December 2019) & US (£13.5m of liabilities) defined benefit pension schemes compared to Mpac's market capitalisation.
- Currency exposure, trade tariffs, raw material price increases (eg steel, aluminium) and competition.
- Mpac is smaller than its rivals/clients (eg German and Italian) and could see margins squeezed.
- Slower than expected growth, higher costs and/or lower cash generation.
- Industry suffers occasionally from lumpy orders, protracted customer purchasing decisions and irregular cashflows over the period end.
- Long term trend towards clients outsourcing production to 'low cost' contract manufacturers.
- Continued industry consolidation could impact pricing and margins.

Historical results				
Mpac plc - continuing (December year end)	2016 Act £'000s	2017 Act £'000s	2018 Act £'000s	2019 Act £'000s
Closing orderbook	25,500	34,400	53,100	52,200
<i>Growth</i>		34.9%	54.4%	-1.7%
Equipment	28,800	40,400	46,200	69,400
Service	12,700	13,000	12,100	19,400
Turnover	41,500	53,400	58,300	88,800
<i>Equipment</i>		40.3%	14.4%	50.2%
<i>Service</i>		2.4%	-6.9%	60.3%
Total % YoY growth		28.7%	9.2%	52.3%
Equipment	5,400	9,200	9,300	18,200
Service	5,600	5,300	4,700	7,800
Total gross margin	11,000	14,500	14,000	26,000
<i>Equipment</i>	18.8%	22.8%	20.1%	26.2%
<i>Service</i>	44.1%	40.8%	38.8%	40.2%
% gross margin	26.5%	27.2%	24.0%	29.3%
EBITDA	450	2,200	2,200	9,800
<i>% Margin</i>	1.1%	4.1%	3.8%	11.0%
Distribution	-5,300	-5,400	-5,000	-7,200
Administration	-6,600	-7,300	-7,200	-10,300
Other	-300	-500	-400	-800
Adjusted EBIT	-1,200	1,300	1,400	7,700
<i>% Operating Margin</i>	-2.9%	2.4%	2.4%	8.7%
Underlying interest charge	-330	-170	0	-200
Adjusted Profit before Tax	-1,530	1,130	1,400	7,500
Adjusted EPS (p)	-6.0p	4.2p	4.5p	39.5p
<i>EPS growth rate</i>			7.5%	777.7%
Dividend (p)	1.3p	0.0p	0.0p	1.5p
<i>Yield</i>	0.5%	0.0%	0.0%	0.6%
Reported sharecount (Ks - incl Treasury)	20,172	20,172	20,172	20,172
Valuation benchmarks				
<i>P/E ratio</i>		56.1	52.2	5.9
<i>PER (adjusted for pension recovery payments)</i>				
<i>EV/Sales (pension adjusted)</i>	1.37	1.06	0.97	0.64
<i>EV/EBITDA (pension adjusted)</i>		25.8	25.8	5.8
<i>EV/EBIT (pension adjusted)</i>		43.6	40.5	7.4
<i>PEG ratio</i>				
<i>Corporate tax rate</i>	-20.0%	-26.5%	-35.9%	5.2%
<i>EBITDA drop through rate</i>			0.0%	24.9%
<i>Return on equity (%)</i>		1.9%	2.2%	16.6%
Net cash/(debt)	800	29,400	27,000	18,000
Information only - Estimated non-underlying Pension charges				
UK pension recovery payments			-1,900	-1,940
Topup UK pension payments above £5.5m EBIT			0	-726
UK pension admin costs			-900	-1,200
UK tax shield			532	735
US pension recovery payments (net tax shield)			-790	-790
Cashflow effect			-3,058	-3,921
Net cash per share		146	134	89
Net assets / diluted share (p)	175	212	201	235
Shareprice (p)	235p			

Source: Equity Development. Mpac's EV has been adjusted for pension. The cost of UK PPF levy is included within EBIT.



Investor Access

Hannah Crowe

Direct: 0207 065 2692

Tel: 0207 065 2690

hannah@equitydevelopment.co.uk

Equity Development Limited is regulated by the Financial Conduct Authority

Equity Development Limited ('ED') is retained to act as financial adviser for various clients, some or all of whom may now or in the future have an interest in the contents of this document and/or in the Company. In the preparation of this report ED has taken professional efforts to ensure that the facts stated herein are clear, fair and not misleading, but make no guarantee as to the accuracy or completeness of the information or opinions contained herein.

The research in this document has been produced in accordance with COBS 12.3 as Non-Independent Research and is a marketing communication. This document is not directed at, may not be suitable for and should not be relied on by anyone who is not an investment professional including retail clients. It does not constitute a personal investment recommendation and recipients must satisfy themselves that any dealing is appropriate in the light of their own understanding, appraisal of risk and reward, objectives, experience, and financial and operational resources. Research on its client companies produced and distributed by ED is normally commissioned and paid for by those companies themselves ('issuer financed research') and as such is deemed to be 'non-independent research' but is 'objective' in that the authors are stating their own opinions. This report has not been produced under legal requirements designed for independent research.

ED may in the future provide, or may have in the past provided, investment banking services to its client companies. For ED's employees and consultants there are rules to prevent dealing in the shares of client companies whilst notes are being prepared, or immediately after the note's release. Publication is achieved by a new note being freely available from the ED website. ED's engagement with corporate clients is governed by the laws of England & Wales. In the UK, companies quoted on AIM are subject to lighter due diligence than shares quoted on the main market and are therefore more likely to carry a higher degree of risk than main market companies.

This report is being provided to relevant persons by ED to provide background information about Mpac Group plc. This document does not constitute, nor form part of, and should not be construed as, any offer for sale or purchase of (or solicitation of, or invitation to make any offer to buy or sell) any Securities (which may rise and fall in value). Nor shall it, or any part of it, form the basis of, or be relied on in connection with, any contract or commitment whatsoever. Self-certification by investors can be completed free of charge at www.fisma.org

More information is available on our website

www.equitydevelopment.co.uk

Equity Development, 15 Eldon Street, London, EC2M 7LD. Contact: info@equitydevelopment.co.uk 0207 065 2690